| Mrs Alison Dealmeida, MA, CCC-SLP | |
|
18 Mansfield Ave, East Brunswick, NJ 08816-3026 | |
| (908) 208-3477 | |
| Not Available |
| Full Name | Mrs Alison Dealmeida |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 18 Mansfield Ave, East Brunswick, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265842686 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Secondary |
| 235Z00000X | Speech-language Pathologist | 41YS00755400 (New Jersey) | Primary |
| Provider Name | At Home By Enhance Therapies Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1124603246 PECOS PAC ID: 4183033210 Enrollment ID: O20210503001929 |
News Archive
At 12 months the NEVO™ Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus® Liberte® according to new data presented today from the NEVO™ RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.
Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).
To grow and spread, tumors need new blood vessels, a process called angiogenesis. One growth factor that causes angiogenesis has been identified - vascular endothelial growth factor or VEGF - and drugs to inhibit VEGF are already in use. But not all tumors respond to the therapy initially or over the long term. Thus new growth factors need to be identified to aid in developing the next generation of angiogenesis inhibitors.
Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Alison Dealmeida, MA, CCC-SLP 18 Mansfield Ave, East Brunswick, NJ 08816-3026 Ph: (908) 208-3477 | Mrs Alison Dealmeida, MA, CCC-SLP 18 Mansfield Ave, East Brunswick, NJ 08816-3026 Ph: (908) 208-3477 |
News Archive
At 12 months the NEVO™ Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus® Liberte® according to new data presented today from the NEVO™ RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.
Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).
To grow and spread, tumors need new blood vessels, a process called angiogenesis. One growth factor that causes angiogenesis has been identified - vascular endothelial growth factor or VEGF - and drugs to inhibit VEGF are already in use. But not all tumors respond to the therapy initially or over the long term. Thus new growth factors need to be identified to aid in developing the next generation of angiogenesis inhibitors.
Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.
› Verified 3 days ago
Mrs. Judy Adornati, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4 Cornwall Dr Ste 101, East Brunswick, NJ 08816 Phone: 732-210-7241 | |
Mrs. Jennifer Harmon, M.A. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 44 Milltown Rd, East Brunswick, NJ 08816 Phone: 732-238-1664 | |
Nicole Schultz, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 Irene Ct, East Brunswick, NJ 08816 Phone: 732-201-7002 | |
Rewa Atre, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 579 Cranbury Rd Ste I, East Brunswick, NJ 08816 Phone: 732-313-5458 | |
Orit Binshtock, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 24 Bunker Hill Run, East Brunswick, NJ 08816 Phone: 732-322-4506 | |
Lauren Grandal, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 281 Summerhill Rd, East Brunswick, NJ 08816 Phone: 908-358-6064 | |
Miss Mary Ann Theresa Lombardo, M.A.;CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 394 Carhart Ct, East Brunswick, NJ 08816 Phone: 917-670-7862 |